Surgical Treatment of Primary Mast Cell Tumor in Mucosal Surface of Lower Lip in a Dog: A Case Report

Main Article Content

Ensiye Sajadian Jaghargh
Ali Mirshahi
Hanieh Shaterzadeh Yazdi

Abstract

Introduction: Mast cell tumors (MCTs) have been described as a form of cancer affecting a specific type of blood cell that typically plays a role in the body's reaction to allergens and inflammatory processes. The MCTs have been classified as skin tumors in dogs which can also affect other areas of the body, such as the spleen, liver, gastrointestinal tract, and bone marrow. The present study investigated the clinical and histological signs, biological behavior, and treatment of primary oral mast cell tumors.


Case report: A 3-year-old neutered female, weighing 18 kg and classified as a medium mixed breed, was referred to a veterinary clinic in Mashhad (Iran) due to the presence of a pink, lobulated mucosal mass located on the internal surface of her lower lip. Although the vital signs were normal, clinical examination, radiology, and an incisional biopsy were performed from the lesion site under general anesthesia for histology study. Histopathological features were similar to those of mastocytoma in this case. On presentation, no concurrent mass was found on other sides of the body. Mandibular lymph nodes were not enlarged; however, the incisor teeth of the mandible were loosed. Accordingly, the primary oral MCTs were diagnosed. The surgery was done and After a follow-up period of 150 days post-excisional surgery for a Mast cell tumor, the patient remained alive and exhibited no visible signs of tumor recurrence or surgical complications.


Conclusion: The current case report defined a primary Mast cell tumor with slow tumor growth and without metastasis in the mucosal surface of the lower lip in a dog treated by complete excisional surgery only, unlike some previous studies of primary oral MCTs in dogs with aggressive biological behaviors.       

Article Details

How to Cite
Sajadian Jaghargh, E., Mirshahi, A., & Shaterzadeh Yazdi, H. (2024). Surgical Treatment of Primary Mast Cell Tumor in Mucosal Surface of Lower Lip in a Dog: A Case Report . Small Animal Advances, 3(3), 22–26. Retrieved from https://saa.rovedar.com/index.php/SAA/article/view/24
Section
Case Report

References

Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q. 2004; 26(4): 156-69. DOI: 10.1080/01652176.2004.9695178

Garrett LD. Canine mast cell tumors: Diagnosis, treatment, and prognosis. Vet Med. 2014; 5: 49-58. DOI: 10.2147/VMRR.S41005

Khoo A, Lane A, and Wyatt K. Intranasal mast cell tumor in the dog: A case series. Can Vet J. 2017; 58(8): 851-854. PMID: 5508967

Mutz ML, Boudreaux BB, Royal A, Merchant S, Pucheu-Haston C, Griffith EH, et al. Cytologic comparison of the percentage of mast cells in lymph node aspirate samples from clinically normal dogs versus dogs with allergic dermatologic disease and dogs with cutaneous mast cell tumors. J Am Vet Med Assoc. 2017; 251(4): 421-428. DOI: 10.2460/javma.251.4.421

Elliott JW, Cripps P, Blackwood L, Berlato D, Murphy S, and Grant IA. Canine oral mucosal mast cell tumours. Vet Comp Oncol. 2016; 14(1): 101-111. DOI: 10.1111/vco.12071

Shoop SJW, Marlow S, Church DB, English K, McGreevy PD, Stell AJ, et al. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol. 2017; 2: 1. DOI: 10.1186/2052-6687-2-1

Hume CT, Kiupel M, Rigatti L, Shofer FS, Skorupski KA, and Sorenmo KU. Outcomes of dogs with grade 3 mast cell tumors: 43 Cases (1997- 2007). J Am Anim Hosp Assoc. 2011; 47(1): 37-44. DOI: 10.5326/JAAHA-MS-5557

Patnaik AK, MacEwen EG, Black AP, and Luckow S. Extracutaneous mast-cell tumor in the dog. Vet Pathol. 1982; 19(6): 608-615. DOI: 10.1177/030098588201900603

Shekell CC, Thomson MJ, Miller RI, and Mackie JT. Primary tonsillar mast cell tumour in a dog. Aust Vet J. 2018; 96(5): 184-187. DOI: 10.1111/avj.12693

Linde KJ, Stockdale SL, Mison MB, and Perry JA. The effect of prednisone on histologic and gross characteristics in canine mast cell tumors. Can Vet J. 2021; 62(1): 45-50. PMID: 33390598

Radlinsky M, and Fossum TW. Small animal surgery textbook. 5th ed. Philadelphia: Elsevier Health Sciences; 2019. p. 337-338.

Hillman LA, Garrett LD, de Lorimier LP, Charney SC, Borst LB, and Fan TM. Biological behavior of oral and perioral mast cell tumors in dogs: 44 Cases (1996-2006). J Am Vet Med Assoc. 2010; 237(8): 936-942. DOI: 10.2460/javma.237.8.936

Gieger TL, Theon AP, Werner JA, McEntee MC, Rassnick KM, and DeCock HEV. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 Cases (1990- 2001). J Vet Intern Med. 2003; 17(5): 687-692. DOI: 10.1111/j.1939-1676.2003.tb02501.x

Weishaar KM, Thamm DH, Worley DR, and Kamstock DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Pathol. 2014; 151(4): 329-338. DOI: 10.1016/j.jcpa.2014.07.004

Malinowski C. Canine and feline nasal neoplasia. Clin Tech Small Anim Pract. 2006; 21(2): 89-94. DOI: 10.1053/j.ctsap.2005.12.016

Khodakaram-Tafti A, Eshraghi M, Geramizadeh B, Shaterzadeh-Yazdi H, and Taghipur-Bazargani T. Immunohistochemical and morphopathological features of multiple cutaneous mast cell tumor in a cow. Braz J Vet Pathol. 2015; 8(2): 68-71. Available at: https://www.bvs-vet.org.br/vetindex/periodicos/brazilian-journal-veterinary-pathology/8-(2015)-2/immunohistochemical-and-morphopathological-features-of-multiple-cutane/

Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med. 1999. 13(6): 601-605. DOI: 10.1892/0891-6640(1999)013%3C0601:tocmct%3E2.3.co;2

McCaw DL, Miller MA, Ogilvie GK, Withrow SJ, Brewer Jr WG, Klein MK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med. 1994; 8(6): 406-408. DOI: 10.1111/j.1939-1676.1994.tb03259.x

London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009; 15(11): 3856-3865. DOI: 10.1158/1078-0432.CCR-08-1860

Iodence AE, Wallace ML, Grimes JA, and Schmiedt CW. Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications. J Am Vet Med Assoc. 2022; 260(S1): S88-S95. DOI: 10.2460/javma.20.09.0488